Gross profit
Flow – sum over the period · $B
Q2 2026
73.9a$B
derived
All values (42)
| Period | Value ($B) | Status |
|---|---|---|
| Q2 2026 | 73.9 | derived |
| Q1 2026 | 68.6 | derived |
| Q4 2025 | 68.1 | derived |
| Q3 2025 | 61.0 | derived |
| Q2 2025 | 57.4 | derived |
| Q1 2025 | 53.9 | derived |
| Q4 2024 | 55.9 | derived |
| Q3 2024 | 51.8 | derived |
| Q2 2024 | 49.2 | derived |
| Q1 2024 | 46.8 | derived |
| Q4 2023 | 48.7 | derived |
| Q3 2023 | 43.5 | derived |
| Q2 2023 | 42.7 | derived |
| Q1 2023 | 39.2 | derived |
| Q4 2022 | 40.7 | derived |
| Q3 2022 | 37.9 | derived |
| Q2 2022 | 39.6 | derived |
| Q1 2022 | 38.4 | derived |
| Q4 2021 | 42.3 | derived |
| Q3 2021 | 37.5 | derived |
| Q2 2021 | 35.7 | derived |
| Q1 2021 | 31.2 | derived |
| Q4 2020 | 30.8 | derived |
| Q3 2020 | 25.1 | derived |
| Q2 2020 | 19.7 | derived |
| Q1 2020 | 22.2 | derived |
| Q4 2019 | 25.1 | derived |
| Q3 2019 | 22.9 | derived |
| Q2 2019 | 21.6 | derived |
| Q1 2019 | 20.3 | derived |
| Q4 2018 | 21.4 | derived |
| Q3 2018 | 19.5 | derived |
| Q2 2018 | 18.8 | derived |
| Q1 2018 | 17.7 | derived |
| Q4 2017 | 18.1 | derived |
| Q3 2017 | 16.6 | derived |
| Q2 2017 | 15.6 | derived |
| Q1 2017 | 15.0 | derived |
| Q4 2016 | 15.4 | derived |
| Q3 2016 | 13.8 | derived |
| Q2 2016 | 13.4 | derived |
| Q1 2016 | 12.6 | derived |
CSV with all sources · Technical ID: gross_profit
More metrics for Alphabet
Income statement
Balance sheet
Debt and interest
Sources & calculation
- Value
- $73.9B (derived)
- Period
- Q2 2026, ended Jun 30, 2026 · quarterly value (3 months, not cumulative)
- Calculation
- gross_profit = Revenue 119,796M − Cost of revenue 45,943M = $73.9B (Summanden: berichtete SEC-Werte derselben Periode)
- Source
- 10-Q, filed Jul 23, 2026 · 0001652044-26-000071
- Location
- gross_profit = + revenue − cogs
- Confidence
- 0.95 – berechnet aus berichteten SEC-Werten derselben Periode (e.g. SG&A = S&M + G&A)
Versions
| v1 | $73.9B | Jul 23, 2026 | 10-Q 0001652044-26-000071 | derived · confidence 0.95 · current |